1月5日 - ** 药物开发商Neumora Therapeutics NMRA.O股价盘前上涨11.45%至1.81美元
** 该公司称其试验性药物NMRA-511在治疗阿尔茨海默病患者躁动的早期研究中取得了积极成果
** 该公司表示，躁动是一种令人痛苦的症状，通常会导致更早的长期护理安排
** 试验涉及 80 名患者；药物对焦虑程度高的患者效果最佳 - NMRA
** 公司称副作用大多较轻，包括感冒、泌尿系统感染和头痛
** 阿尔茨海默氏症是一种脑部疾病，会导致记忆力减退和思维混乱
** 截至上次收盘，该公司股价在过去一年中下跌了 ~7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.